Summary

  • On 9 March 2026, Nexperia China said it had achieved small-batch production of bipolar discrete devices on 12-inch, or 300 mm, wafers.
  • Nexperia’s own manufacturing pages describe its European front-end fabs as 6- and 8-inch operations; a larger wafer can improve unit economics but does not establish an advanced process node.
  • The source of the 300 mm wafers, production yield, qualification status and sustainable volume were not disclosed, and Nexperia’s Dutch headquarters declined to comment to Reuters.

A milestone claimed by one side of a corporate split

Reuters reported on 9 March that Nexperia China announced small-batch production of 12-inch-wafer bipolar discrete devices on its Chinese social-media account. A related account from the same reporting described bipolar discretes, Schottky rectifiers and electrostatic-discharge devices. The words “breakthrough” and “independent R&D and mass-production capability” came from the Chinese unit. They are not independent measurements of capacity, yield or customer acceptance.

The distinction is important because the corporate dispute has divided public claims. Reuters said Nexperia China did not immediately identify its wafer source and the European headquarters declined to comment. WingSkySemi, a Shanghai 300 mm fab controlled by Wingtech’s founder, was identified as a possible source, not a confirmed supplier. This article therefore treats production as a company claim whose scale and supply chain still need verification.

Wafer diameter is not a process-node ranking

Nexperia’s manufacturing page says Hamburg produces on 6- and 8-inch wafers and Manchester also runs 6- and 8-inch lines. Its 2024 Hamburg investment announcement describes a conversion toward 200 mm production, not 300 mm. That supports a real difference in wafer format between the Chinese claim and the disclosed European front-end footprint.

A 300 mm wafer provides more surface area and can spread fixed processing costs across more dies. It says nothing by itself about lithography, feature size, performance, automotive qualification or yield. Nexperia’s product mix here consists of mature discrete components, not leading-edge processors. Calling the Chinese operation technologically “more advanced” without those qualifications would overstate the evidence.

The supply-chain redesign is the stronger signal

Nexperia’s 2024 sustainability report placed front-end wafer fabs in Hamburg and Manchester and listed Dongguan and Wuxi as assembly sites. The 300 mm announcement therefore points to a change in how the Chinese operation obtains and processes wafers after supplies from Europe were disrupted; it does not, on the cited record, prove that every front-end step has moved inside Nexperia China.

Nexperia’s March 2026 response disputed claims from management of its China entities about IT access and production. That exchange is evidence of a live operational conflict, not a neutral technical audit. Buyers need lot-level traceability, quality certification and continuity data before assuming the new route is interchangeable with the previous European-wafer/Chinese-assembly chain.

Ownership does not settle operational control

Nexperia said in 2019 that Wingtech had acquired a controlling stake, while the Dutch government said in October 2025 that it invoked the Goods Availability Act over governance shortcomings and risks to European technological capability. Those facts explain the stakes but do not resolve which side’s 2026 operating claims are correct.

The next decisive evidence would be the named wafer supplier, qualified process flows, audited yield, automotive approvals, recurring shipment volumes and customer acceptance. Until those arrive, the defensible conclusion is narrow: Nexperia China says it has begun small-batch 300 mm production, creating a plausible new supply route whose durability and independence remain unproven.